Coherus Oncology (CHRS) EV to CFO (2014 - 2026)

Coherus Oncology has disclosed EV to CFO across 13 years of filings, most recently posting 1.79 for Q2 2026.

• In Q2 2026, EV to CFO fell 154.54% year-over-year to 1.79; the TTM figure through Jun 2026 stood at 0.6 (down 141.32% YoY), while the FY2025 annual figure was 0.0, up 100.04% from the prior year.
• EV to CFO came in at 1.79 for Q2 2026 at Coherus Oncology, down from 1.62 in the prior quarter.
• In the past five years, EV to CFO ranged from a high of 3.28 in Q2 2025 to a low of 19.78 in Q4 2023.
• Average EV to CFO over 5 years is 4.0, with a median of 1.7 recorded in 2026.
• Year-over-year, EV to CFO slumped 356.85% in 2023 and surged 388.66% in 2025.
• Over 5 years, EV to CFO stood at 4.33 in 2022, then tumbled by 356.85% to 19.78 in 2023, then soared by 105.93% to 1.17 in 2024, then tumbled by 99.63% to 0.0 in 2025, then plunged by 41543.42% to 1.79 in 2026.
• Per Business Quant data, the three most recent EV to CFO figures were 1.79 in Q2 2026, 1.62 in Q1 2026, and 0.0 in Q4 2025.